Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimer's Disease and Cognitive Decline

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2020 Oct 12

PMID 33044176

Citations 9

Authors

Cynthia M Stonnington

Stefanie N Velgos

Yinghua Chen

Sameena Syed

Matt Huentelman

Pradeep Thiyyagura

Wendy Lee

Ryan Richholt

Richard J Caselli

Dona E C Locke

Bai Lu

Eric M Reiman

Yi Su

Kewei Chen

Affiliations

Soon will be listed here.

Abstract

Background: Whether brain-derived neurotrophic factor (BDNF) Met carriage impacts the risk or progression of Alzheimer's disease (AD) is unknown.

Objective: To evaluate the interaction of BDNF Met and APOE4 carriage on cerebral metabolic rate for glucose (CMRgl), amyloid burden, hippocampus volume, and cognitive decline among cognitively unimpaired (CU) adults enrolled in the Arizona APOE cohort study.

Methods: 114 CU adults (mean age 56.85 years, 38% male) with longitudinal FDG PET, magnetic resonance imaging, and cognitive measures were BDNF and APOE genotyped. A subgroup of 58 individuals also had Pittsburgh B (PiB) PET imaging. We examined baseline CMRgl, PiB PET amyloid burden, CMRgl, and hippocampus volume change over time, and rate of change in cognition over an average of 15 years.

Results: Among APOE4 carriers, BDNF Met carriers had significantly increased amyloid deposition and accelerated CMRgl decline in regions typically affected by AD, but without accompanying acceleration of cognitive decline or hippocampal volume changes and with higher baseline frontal CMRgl and slower frontal decline relative to the Val/Val group. The BDNF effects were not found among APOE4 non-carriers.

Conclusion: Our preliminary studies suggest that there is a weak interaction between BDNF Met and APOE4 on amyloid-β plaque burden and longitudinal PET measurements of AD-related CMRgl decline in cognitively unimpaired late-middle-aged and older adults, but with no apparent effect upon rate of cognitive decline. We suggest that cognitive effects of BDNF variants may be mitigated by compensatory increases in frontal brain activity-findings that would need to be confirmed in larger studies.

Citing Articles

Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer's Disease.

Forsell P, Parrado Fernandez C, Nilsson B, Sandin J, Nordvall G, Segerdahl M Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204102 PMC: 11357672. DOI: 10.3390/ph17080997.

Potential role of ɛ4 allele as a modifier for the association of Val66Met polymorphisms and cognitive impairment in community-dwelling older adults.

Ji S, Kang J, Han C, Xu X, Chen M, Chen J Front Aging Neurosci. 2024; 16:1330193.

PMID: 38374884 PMC: 10876185. DOI: 10.3389/fnagi.2024.1330193.

DAT1 and BDNF polymorphisms interact to predict Aβ and tau pathology.

Ciampa C, Morin T, Murphy A, La Joie R, Landau S, Berry A Neurobiol Aging. 2023; 133:115-124.

PMID: 37948982 PMC: 10872994. DOI: 10.1016/j.neurobiolaging.2023.10.009.

Impact of transcranial direct current stimulation on white matter microstructure integrity in mild cognitive impairment patients according to effect modifiers as risk factors for Alzheimer's disease.

Kang D, Wang S, Um Y, Kim S, Kim T, Kim D Front Aging Neurosci. 2023; 15:1234086.

PMID: 37744398 PMC: 10517264. DOI: 10.3389/fnagi.2023.1234086.

Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer's Disease.

Parrado Fernandez C, Juric S, Backlund M, Dahlstrom M, Madjid N, Lidell V Int J Mol Sci. 2023; 24(13).

PMID: 37446337 PMC: 10342804. DOI: 10.3390/ijms241311159.

References

Caselli R, Reiman E, Locke D, Hutton M, Hentz J, Hoffman-Snyder C . Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol. 2007; 64(9):1306-11. DOI: 10.1001/archneur.64.9.1306. View

Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H . Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol. 2009; 65(6):650-7. DOI: 10.1002/ana.21696. View

Lim Y, Villemagne V, Laws S, Ames D, Pietrzak R, Ellis K . BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiol Aging. 2013; 34(11):2457-64. DOI: 10.1016/j.neurobiolaging.2013.05.006. View

Morris J, Roe C, Xiong C, Fagan A, Goate A, Holtzman D . APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010; 67(1):122-31. PMC: 2830375. DOI: 10.1002/ana.21843. View

Lamb Y, Thompson C, McKay N, Waldie K, Kirk I . The brain-derived neurotrophic factor (BDNF) val66met polymorphism differentially affects performance on subscales of the Wechsler Memory Scale - Third Edition (WMS-III). Front Psychol. 2015; 6:1212. PMC: 4538220. DOI: 10.3389/fpsyg.2015.01212. View

Richter-Schmidinger T, Alexopoulos P, Horn M, Maus S, Reichel M, Rhein C . Influence of brain-derived neurotrophic-factor and apolipoprotein E genetic variants on hippocampal volume and memory performance in healthy young adults. J Neural Transm (Vienna). 2010; 118(2):249-57. DOI: 10.1007/s00702-010-0539-8. View

Boots E, Schultz S, Clark L, Racine A, Darst B, Koscik R . Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention. Neurology. 2017; 88(22):2098-2106. PMC: 5447398. DOI: 10.1212/WNL.0000000000003980. View

Nielsen H, Chen K, Lee W, Chen Y, Bauer 3rd R, Reiman E . Peripheral apoE isoform levels in cognitively normal APOE ε3/ε4 individuals are associated with regional gray matter volume and cerebral glucose metabolism. Alzheimers Res Ther. 2017; 9(1):5. PMC: 5282900. DOI: 10.1186/s13195-016-0231-9. View

Reiman E, Chen K, Alexander G, Caselli R, Bandy D, Osborne D . Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A. 2005; 102(23):8299-302. PMC: 1149416. DOI: 10.1073/pnas.0500579102. View

10.

Reiman E, Uecker A, Caselli R, Lewis S, Bandy D, de Leon M . Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol. 1998; 44(2):288-91. DOI: 10.1002/ana.410440226. View

11.

Adamczuk K, De Weer A, Nelissen N, Chen K, Sleegers K, Bettens K . Polymorphism of brain derived neurotrophic factor influences β amyloid load in cognitively intact apolipoprotein E ε4 carriers. Neuroimage Clin. 2013; 2:512-20. PMC: 3777754. DOI: 10.1016/j.nicl.2013.04.001. View

12.

Fischl B, Salat D, Busa E, Albert M, Dieterich M, Haselgrove C . Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002; 33(3):341-55. DOI: 10.1016/s0896-6273(02)00569-x. View

13.

Small G, Ercoli L, Silverman D, Huang S, Komo S, Bookheimer S . Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2000; 97(11):6037-42. PMC: 18554. DOI: 10.1073/pnas.090106797. View

14.

Barbey A, Colom R, Paul E, Forbes C, Krueger F, Goldman D . Preservation of general intelligence following traumatic brain injury: contributions of the Met66 brain-derived neurotrophic factor. PLoS One. 2014; 9(2):e88733. PMC: 3935849. DOI: 10.1371/journal.pone.0088733. View

15.

Knopman D, Jack Jr C, Lundt E, Weigand S, Vemuri P, Lowe V . Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiol Aging. 2016; 46:32-42. PMC: 5018437. DOI: 10.1016/j.neurobiolaging.2016.06.003. View

16.

Cechova K, Andel R, Angelucci F, Chmatalova Z, Markova H, Laczo J . Impact of APOE and BDNF Val66Met Gene Polymorphisms on Cognitive Functions in Patients with Amnestic Mild Cognitive Impairment. J Alzheimers Dis. 2019; 73(1):247-257. DOI: 10.3233/JAD-190464. View

17.

Reiman E, Chen K, Liu X, Bandy D, Yu M, Lee W . Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009; 106(16):6820-5. PMC: 2665196. DOI: 10.1073/pnas.0900345106. View

18.

Cerasa A, Tongiorgi E, Fera F, Gioia M, Valentino P, Liguori M . The effects of BDNF Val66Met polymorphism on brain function in controls and patients with multiple sclerosis: an imaging genetic study. Behav Brain Res. 2009; 207(2):377-86. DOI: 10.1016/j.bbr.2009.10.022. View

19.

Caselli R, Dueck A, Osborne D, Sabbagh M, Connor D, Ahern G . Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med. 2009; 361(3):255-63. PMC: 2928998. DOI: 10.1056/NEJMoa0809437. View

20.

Oroszi G, Lapteva L, Davis E, Yarboro C, Weickert T, Roebuck-Spencer T . The Met66 allele of the functional Val66Met polymorphism in the brain-derived neurotrophic factor gene confers protection against neurocognitive dysfunction in systemic lupus erythematosus. Ann Rheum Dis. 2006; 65(10):1330-5. PMC: 1798324. DOI: 10.1136/ard.2006.051623. View